But the body composition data is even more impressive: About 60-62% of total weight loss is fat mass
[2] Dulaglutide (Trulicity), another once-weekly injectable GLP-1 agonist, demonstrates a somewhat more favourable gastrointestinal tolerability profile in some studies, with nausea reported in approximately 8-12% of patients at lower doses, though rates increase with higher doses (3
The free tracker at the top of this page is built for exactly this kind of quick daily check-in
10, 2026 (GLOBE NEWSWIRE) -- This article is for informational purposes only and does not constitute medical advice
Machado, L., Goncalves, P., Barreto, C., Perazzolo, L.M., and Rosa, R.D., J
An Overview of Glp-1 Medical Weight Loss Glucagon-like peptide-1 receptor agonists, better known as Glp-1 agonists or simply Glp-1s, first gained U.S